410 related articles for article (PubMed ID: 29096861)
1. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
[TBL] [Abstract][Full Text] [Related]
2. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H; Vogt A;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
4. First data from the German Lipoprotein Apheresis Registry (GLAR).
Schettler VJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Ramlow W; Blume H;
Atheroscler Suppl; 2015 May; 18():41-4. PubMed ID: 25936303
[TBL] [Abstract][Full Text] [Related]
5. The German Lipoprotein Apheresis Registry-Summary of the ninth annual report.
Schettler VJJ; Peter C; Zimmermann T; Julius U; Roeseler E; Schlieper G; Heigl F; Grützmacher P; Löhlein I; Klingel R; Hohenstein B; Ramlow W; Vogt A;
Ther Apher Dial; 2022 Dec; 26 Suppl 1():81-88. PubMed ID: 36468337
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
[TBL] [Abstract][Full Text] [Related]
7. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
[TBL] [Abstract][Full Text] [Related]
9. Current view: indications for extracorporeal lipid apheresis treatment.
Schettler V; Neumann CL; Hulpke-Wette M; Hagenah GC; Schulz EG; Wieland E;
Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):15-9. PubMed ID: 22528134
[TBL] [Abstract][Full Text] [Related]
10. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.
Schettler VJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F;
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):14-20. PubMed ID: 25652812
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?
Heigl F; Pflederer T; Klingel R; Hettich R; Lotz N; Reeg H; Schettler VJJ; Roeseler E; Grützmacher P; Hohenstein B; Julius U
Atheroscler Suppl; 2019 Dec; 40():23-29. PubMed ID: 31818446
[TBL] [Abstract][Full Text] [Related]
12. Actual situation of lipoprotein apheresis in Saxony in 2013.
Emmrich U; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a)-apheresis in the light of new drug developments.
Vogt A
Atheroscler Suppl; 2017 Nov; 30():38-43. PubMed ID: 29096859
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
Klingel R; Heibges A; Fassbender C
Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
Klingel R; Heibges A; Fassbender C;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
[TBL] [Abstract][Full Text] [Related]
17. Detailed description of the cardiovascular situation in patients who have started lipoprotein apheresis treatment.
Schampera S; Fischer S; Weiss N; Julius U
Atheroscler Suppl; 2015 May; 18():209-14. PubMed ID: 25936328
[TBL] [Abstract][Full Text] [Related]
18. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
Schatz U; Tselmin S; Müller G; Julius U; Hohenstein B; Fischer S; Bornstein SR
Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017.
Pottle A; Thompson G; Barbir M; Bayly G; Cegla J; Cramb R; Dawson T; Eatough R; Kale V; Neuwirth C; Nicholson K; Payne J; Scott J; Soran H; Walji S; Watkins S; Weedon H; Nath Datta DB
Atherosclerosis; 2019 Nov; 290():44-51. PubMed ID: 31563836
[TBL] [Abstract][Full Text] [Related]
20. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.
Hohenstein B; Tselmin S; Bornstein SR; Julius U
Atheroscler Suppl; 2017 Nov; 30():28-32. PubMed ID: 29096851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]